Abstract
Background
As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial.
Methods
Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID-19, asymptomatic convalescents, both with PCR-positive at the moment of diagnosis; and individuals with subclinical infection detected by viral-specific IgG. They received a single intramuscular injection of the FINLAY-FR-1A vaccine (50 µg of the recombinant dimeric receptor binding domain). The primary outcomes were safety and reactogenicity, assessed over 28 days after vaccination. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following vaccination was evaluated by ELISA and live-virus neutralization test. The effector T cellular response was also assessed. Cuban Public Registry of Clinical Trials, WHO-ICTRP: https://rpcec.sld.cu/en/trials/RPCEC00000349-En.
Findings
No serious adverse events were reported. Minor adverse events were found, the most common, local pain: 3 (10%) and redness: 2 (6·7%). The vaccine elicited a >21 fold increase in IgG anti-RBD antibodies 28 days after vaccination. The median of inhibitory antibody titres (94·0%) was three times greater than that of the COVID-19 convalescent panel. Virus neutralization titres higher than 1:160 were found in 24 (80%) participants. There was also an increase in RBD-specific T cells producing IFN-γ and TNF-α.
Interpretation
A single dose of the FINLAY-FR-1A vaccine against SARS-CoV-2 was an efficient booster of pre-existing natural immunity, with excellent safety profile.
Funding
Partial funding for this study was received from the Project-2020-20, Fondo de Ciencia e Innovación (FONCI), Ministry of Science, Technology and the Environment, Cuba.
【초록키워드】 COVID-19, SARS-CoV-2, IgG, Vaccine, vaccination, reactogenicity, clinical trial, neutralization, technology, Local, ELISA, Environment, Receptor binding domain, Reinfection, T cell, Humoral response, Asymptomatic, clinical, adverse event, Mild, convalescent, registry, funding, safety profile, booster, single dose, IFN-γ, TNF-α, Antibody titre, cellular response, natural immunity, vaccine immunogenicity, Anti-RBD antibody, Intramuscular injection, subclinical infection, Science, Serious Adverse Event, Participants, Primary outcome, minor, individual, PCR-positive, secondary outcome, finding, Cuba, inhibitory, Public, greater, Partial, reported, evaluated, median, increase in, producing, elicited, dimeric, baseline, Virus neutralization titre, 【제목키워드】 COVID-19, SARS-CoV-2, Vaccine, clinical trial, Open-label, neutralization, single dose, ENhance,